- Home
- UPS vs REGN Comparison
UPS vs REGN Comparison
Compare UPS & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPS
- REGN
- Stock Information
- Founded
- UPS 1907
- REGN 1988
- Country
- UPS United States
- REGN United States
- Employees
- UPS N/A
- REGN N/A
- Industry
- UPS Trucking Freight/Courier Services
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- UPS Industrials
- REGN Health Care
- Exchange
- UPS Nasdaq
- REGN Nasdaq
- Market Cap
- UPS 83.0B
- REGN 63.4B
- IPO Year
- UPS 1999
- REGN 1991
- Fundamental
- Price
- UPS $96.95
- REGN $547.67
- Analyst Decision
- UPS Buy
- REGN Buy
- Analyst Count
- UPS 19
- REGN 23
- Target Price
- UPS $121.84
- REGN $907.39
- AVG Volume (30 Days)
- UPS 6.0M
- REGN 1.2M
- Earning Date
- UPS 04-29-2025
- REGN 04-29-2025
- Dividend Yield
- UPS 6.77%
- REGN 0.32%
- EPS Growth
- UPS N/A
- REGN 16.49
- EPS
- UPS 6.85
- REGN 39.43
- Revenue
- UPS $90,910,000,000.00
- REGN $14,085,700,000.00
- Revenue This Year
- UPS N/A
- REGN $2.38
- Revenue Next Year
- UPS $1.22
- REGN $7.65
- P/E Ratio
- UPS $14.15
- REGN $14.23
- Revenue Growth
- UPS 1.30
- REGN 7.52
- 52 Week Low
- UPS $90.55
- REGN $520.50
- 52 Week High
- UPS $153.42
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- UPS 44.83
- REGN 38.69
- Support Level
- UPS $93.20
- REGN $542.44
- Resistance Level
- UPS $97.66
- REGN $615.61
- Average True Range (ATR)
- UPS 2.18
- REGN 22.06
- MACD
- UPS 0.57
- REGN -0.13
- Stochastic Oscillator
- UPS 56.65
- REGN 28.57
About UPS United Parcel Service Inc.
As the world's largest parcel delivery company, UPS manages a massive fleet of more than 500 planes and 100,000 vehicles, along with many hundreds of sorting facilities, to deliver an average of about 22 million packages per day to residences and businesses across the globe. UPS' domestic US package operations generate around 65% of total revenue, while international package makes up 20%. Air and ocean freight forwarding and contract logistics make up the remainder.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).